阿司匹林对慢性肾脏病患者心血管结局的影响
在无既往心血管病的TIPS-3随机试验人群中,按eGFR分层分析阿司匹林75 mg/日与安慰剂对心血管复合结局的影响。共5712人随机,平均随访4.6年;eGFR低于60 ml/min/1.73 m2者阿司匹林组主要结局风险低于安慰剂组(HR 0.57),eGFR高于60者两组无显著差异(HR 0.95)。
要点
- eGFR低于60 ml/min/1.73 m2者阿司匹林组主要心血管结局少于安慰剂组(HR 0.57;95%CI 0.34-0.94)。
- eGFR高于60 ml/min/1.73 m2者阿司匹林与安慰剂主要结局无显著差异(HR 0.95;95%CI 0.71-1.27)。
- 按eGFR三分位分析,阿司匹林的主要结局风险降低在较低eGFR水平更大。
核心结论
- 研究结果支持阿司匹林可能降低中重度慢性肾脏病患者的心血管事件。
研究设计与样本
- 国际Polycap研究-3(TIPS-3)试验为随机对照试验,将无既往心血管病者随机分配至阿司匹林75 mg/日或安慰剂。
- 本次分析按eGFR阈值60 ml/min/1.73 m2及eGFR三分位分组,比较阿司匹林与安慰剂对心血管事件的影响。
- 共5712名参与者被随机,平均随访4.6年。
- eGFR低于60 ml/min/1.73 m2者983例(17.2%),平均eGFR 49 ml/min/1.73 m2;eGFR高于60 ml/min/1.73 m2者4729例,平均eGFR 84 ml/min/1.73 m2。
- 主要结局为非致死性心肌梗死、非致死性卒中或心血管死亡的复合终点。
主要发现
- eGFR低于60 ml/min/1.73 m2者中,阿司匹林组502例发生26次主要结局,安慰剂组481例发生39次(HR 0.57;95%CI 0.34-0.94)。
- eGFR高于60 ml/min/1.73 m2者中,阿司匹林组2357例发生90次主要结局,安慰剂组2372例发生95次(HR 0.95;95%CI 0.71-1.27)。
- 按eGFR三分位(低于70、70-90、高于90 ml/min/1.73 m2),阿司匹林对主要结局的风险降低在较低eGFR水平更大:最低三分位HR 0.62(95%CI 0.43-0.91),中间三分位HR 0.96(95%CI 0.62-1.49),最高三分位HR 1.30(95%CI 0.77-2.18)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic kidney disease (CKD) carry a high cardiovascular (CV) risk. Since whether this risk is reduced by aspirin is unclear, we examined if the effect of aspirin on cardiovascular outcomes varied by baseline kidney function in a primary cardiovascular disease prevention trial. The International Polycap Study-3 (TIPS-3) trial had randomized people without previous cardiovascular disease to aspirin (75 mg daily) or placebo. We now examined aspirin versus placebo on cardiovascular events in participants grouped by estimated glomerular filtration rate (eGFR), using a threshold of 60 ml/min/1.73 m2, and by using tertiles of eGFR. The primary outcome was a composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. A total of 5712 participants were randomized with a mean follow-up of 4.6 years. Of these, 983 (17.2%) had an eGFR under 60 ml/min/1.73 m2 (mean eGFR 49 ml/min/1.73 m2) and 4,729 over 60 ml/min/1.73 m2 (mean 84 ml/min/1.73 m2). In participants with an eGFR under 60 ml/min/1.73 m2 there were 26 primary outcomes in 502 participants on aspirin and 39/481 on placebo (hazard ratio 0.57; 95% confidence interval 0.34-0.94). In participants with an eGFR over 60 ml/min/1.73 m2 there were 90 primary outcomes in 2357 participants on aspirin and 95/2372 on placebo (0.95; 0.71-1.27). With tertiles of eGFR under 70, 70-90, and over 90 ml/min/1.73 m2, risk reductions with aspirin for the primary outcome were larger at lower eGFR levels (0.62; 0.43-0.91) for the lowest tertile, (0.96; 0.62-1.49) for the middle, and (1.30; 0.77-2.18) for the highest tertile. Thus, our findings support aspirin may reduce cardiovascular events in people with moderate to advanced stage CKD.
引用
- Mann JFE, Joseph P, Gao P, et al. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2022. PMID: 36341885. doi:10.1016/j.kint.2022.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。